{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:35:23Z","timestamp":1783971323338,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ijantimicag.2014.09.006","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T04:57:24Z","timestamp":1413262644000},"page":"46-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients"],"prefix":"10.1016","volume":"45","author":[{"given":"Laura M.","family":"Blackburn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank P.","family":"Tverdek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0005","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1592\/phco.2005.25.10.1353","article-title":"Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment","volume":"25","author":"Obritsch","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/FTD.0b013e31818b6b2f","article-title":"Suboptimal aminoglycoside dosing in critically ill patients","volume":"30","author":"Rea","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0025","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00005373-200011000-00013","article-title":"Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens","volume":"49","author":"Barletta","year":"2000","journal-title":"J Trauma"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijantimicag.2006.04.015","article-title":"Increased amikacin dosage requirements in burn patients receiving a once-daily regimen","volume":"28","author":"Conil","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0035","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/cc8945","article-title":"Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0040","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1378\/chest.11-1396","article-title":"Introduction to drug pharmacokinetics in the critically ill patient","volume":"141","author":"Smith","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0045","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2165\/00003088-200544100-00002","article-title":"Antimicrobial therapy in critically ill patients","volume":"44","author":"Pea","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2125.1998.00779.x","article-title":"Population pharmacokinetics of gentamicin in patients with cancer","volume":"46","author":"Rosario","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0055","doi-asserted-by":"crossref","first-page":"R291","DOI":"10.1186\/cc2893","article-title":"Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care","volume":"8","author":"Williams","year":"2004","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0060","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/AAC.41.5.1115","article-title":"Pharmacokinetics of gentamicin at traditional versus high doses: implications of once-daily aminoglycoside dosing","volume":"41","author":"Demczar","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0065","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1128\/AAC.3.4.469","article-title":"Pharmacokinetics of the aminoglycoside antibiotic tobramycin in humans","volume":"3","author":"Naber","year":"1973","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0070","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cpt1977213362","article-title":"Kinetic model for gentamicin dosing with the use of individual patient parameters","volume":"21","author":"Sawchuk","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0075","series-title":"Clinical Pharmacokinetics Handbook","first-page":"55","article-title":"Aminoglycoside antibiotics","author":"Bauer","year":"2006"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0085","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00003246-198804000-00004","article-title":"Variability in aminoglycoside pharmacokinetics in critically ill surgical patients","volume":"16","author":"Dasta","year":"1988","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0090","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01706354","article-title":"Gentamicin volume of distribution in critically ill septic patients","volume":"16","author":"Triginer","year":"1990","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0095","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMoa010307","article-title":"Early goal-directed therapy in the treatment of severe sepsis and septic shock","volume":"245","author":"Rivers","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0100","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0105","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00134-002-1313-7","article-title":"Experience with a once-daily dosing program of aminoglycosides in critically ill patients","volume":"28","author":"Bujik","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0110","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","article-title":"Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity","volume":"38","author":"Galvez","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0115","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/140.4.576","article-title":"The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure","volume":"140","author":"Bennett","year":"1979","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0120","unstructured":"Micromedex\u00ae Healthcare Series [Internet database]. Greenwood Village, CO: Thompson Reuters Healthcare."},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0125","unstructured":"Lexi-Comp Online\u2122, Lexi-Drugs Online\u2122. Hudson, OH: Lexi-Comp, Inc."},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0130","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/AAC.00174-11","article-title":"Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients","volume":"55","author":"Pai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0135","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/infdis\/157.2.287","article-title":"In vivo postantibiotic effect in a thigh infection in neutropenic mice","volume":"157","author":"Vogelman","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.09.006_bib0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MJT.0b013e31815adfde","article-title":"An evaluation of amikacin nephrotoxicity in the hematology\/oncology population","volume":"15","author":"Kiel","year":"2008","journal-title":"Am J Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914002933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914002933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T01:04:56Z","timestamp":1565917496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857914002933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0924857914002933"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.09.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}